Aescap logo

Sustained Growth

Aescap 2.0

Aescap 2.0 is an open-end biotech fund for joint account investing in listed companies that develop and/or market next generation medicines. The fund has a focused portfolio, investing in approximately 18 companies from a total pool of over 600 listed companies in the biotech sector. Our significant out-performance of our benchmark, the Nasdaq Biotech Index (NBI), is driven by selecting those companies with an outstanding management team, innovative products and a low risk profile, which are at the same time seriously undervalued.

In order to reduce the risks of investing in this sector the fund diversifies its portfolio over several disease areas, different phases of company development as well as geographical areas. Read more about our strategy here. The Fund’s objective is to enable the development of next generation medicine and in parallel make an annual net return of 20%+ to its investors.
ISIN Code Aescap 2.0: NL0012343958
Net Performance at 30-09-18:

STD YTD 1 month 3 months 6 months 1 year 2 years
95,6% 66,5% 20,6% 32,3% 54,4% 50,9% 75,6%

Download our Fact Sheet
Download our Subscription form
Request our Prospectus

AFM banner

Aescap Venture 1

Back in 2006 Aescap launched its first biotech fund, called Aescap Venture 1. Aescap 1 is a venture capital fund with a fund size of 100 million euro. The fund has invested in 12 private medical biotech companies throughout Europe and is aiming for a fund multiple of 2,4x. So far, Aescap Venture 1 has made several successful divestments and has taken three companies public on Euronext. Today, the portfolio still holds several high potential companies under management that will be divested over the coming years. Aescap Venture 1 is not open to new investors, nor will it make any new investments. In 2015 Aescap Venture 1 Managing Partner Patrick Krol decided to launch Aescap 2.0, a fund for joint account investing in public biotech companies. The reason of his switch from investing in private to public companies was driven by his experience investing in public and private biotech for over 10 years. Patrick’s conclusion was that investing in public biotech companies represents a healthier risk/reward profile. Click here for more information about Aescap Venture 1.